- Home
- MOVE vs KZIA Comparison
MOVE vs KZIA Comparison
Compare MOVE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOVE
- KZIA
- Stock Information
- Founded
- MOVE 2018
- KZIA 1994
- Country
- MOVE United States
- KZIA Australia
- Employees
- MOVE N/A
- KZIA N/A
- Industry
- MOVE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- MOVE Health Care
- KZIA Health Care
- Exchange
- MOVE Nasdaq
- KZIA Nasdaq
- Market Cap
- MOVE 5.3M
- KZIA 5.1M
- IPO Year
- MOVE 2021
- KZIA 1999
- Fundamental
- Price
- MOVE $0.70
- KZIA $6.10
- Analyst Decision
- MOVE Buy
- KZIA Strong Buy
- Analyst Count
- MOVE 1
- KZIA 2
- Target Price
- MOVE $30.00
- KZIA $57.50
- AVG Volume (30 Days)
- MOVE 250.0K
- KZIA 2.6M
- Earning Date
- MOVE 08-13-2025
- KZIA 07-07-2025
- Dividend Yield
- MOVE N/A
- KZIA N/A
- EPS Growth
- MOVE N/A
- KZIA N/A
- EPS
- MOVE N/A
- KZIA N/A
- Revenue
- MOVE $1,013,000.00
- KZIA $1,549,158.00
- Revenue This Year
- MOVE $1,460.71
- KZIA N/A
- Revenue Next Year
- MOVE $96.77
- KZIA N/A
- P/E Ratio
- MOVE N/A
- KZIA N/A
- Revenue Growth
- MOVE N/A
- KZIA 248983.08
- 52 Week Low
- MOVE $0.51
- KZIA $2.86
- 52 Week High
- MOVE $6.97
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- MOVE 47.73
- KZIA 50.96
- Support Level
- MOVE $0.61
- KZIA $5.83
- Resistance Level
- MOVE $0.85
- KZIA $9.60
- Average True Range (ATR)
- MOVE 0.10
- KZIA 1.19
- MACD
- MOVE 0.02
- KZIA -0.29
- Stochastic Oscillator
- MOVE 43.49
- KZIA 18.39
About MOVE Movano Inc.
Movano Inc is developing a platform to deliver purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. its initial commercial product in development is the Evie Ring, a wearable designed specifically for women. The Evie Ring combines health and wellness metrics to give a full picture of one's health, which includes resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.